Document Detail


A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
MedLine Citation:
PMID:  20889729     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Lapatinib is a specific HER1 and 2 targeted tyrosine kinase inhibitor now widely used in combination with chemotherapy in the clinical setting. In this work, we investigated the interactions between lapatinib and specific chemotherapy agents (cisplatin, SN-38, topotecan) in a panel of cell lines [breast (n = 2), lung (n = 2), testis (n = 4)]. A high-sensitivity cell proliferation/cytotoxicity ATP assay and flow cytometry were used to determine cell viability, apoptosis, and the effect of the drugs on cell-cycle distribution. CalcuSyn analysis was employed to formally identify synergistic interactions between drugs. Intracellular concentrations of SN-38 were measured using a novel high-performance liquid chromatography (HPLC) technique. Flow cytometry and HPLC techniques were used to identify the effect of lapatinib on drug influx and efflux pumps, using specific substrates and inhibitors of these pumps. Results showed significant synergy between SN-38, and lapatinib in the majority of cell lines (combination index < 0.75), associated with increased apoptosis. This synergy was not universal but, when observed (Susa S/R, H1975, H358, and MDA-MB-231 cell lines), was related to SN-38 intracellular accumulation (2.2- to 4.8-fold increase, P < 0.05 for each), attributable to the inhibition of the breast cancer-related protein (BCRP) efflux pump by lapatinib. Flow cytometry analysis showed that lapatinib (10 μmol/L) inhibited the efflux of mitoxantrone, a specific substrate of the BCRP pump, in a manner similar to fumitremorgin C, a known BCRP inhibitor, confirming lapatinib as a BCRP inhibitor. This work shows that lapatinib has a direct inhibitory effect on BCRP accounting for the synergistic findings. The synergy is cell line dependent and related to the activity of specific efflux pumps.
Authors:
Jackie Perry; Essam Ghazaly; Christiana Kitromilidou; Eva H McGrowder; Simon Joel; Thomas Powles
Related Documents :
8337699 - Modification of mipafox-induced inhibition of neuropathy target esterase in neuroblasto...
12932699 - Mussel blood cells, resistant to the cytotoxic effects of okadaic acid, do not express ...
11996089 - By-passing of p-glycoprotein using immunoliposomes.
2896069 - Pharmacological and biological evidence for differing mechanisms of doxorubicin resista...
8662299 - Hypotonicity-induced anion fluxes in cells expressing the multidrug-resistance-associat...
11036469 - Multidrug resistance phenotype and paclitaxel (taxol) sensitivity in human renal carcin...
8916219 - Thermotaxis of human trophoblastic cells.
19931389 - Opposing actions of the progesterone metabolites, 5alpha-dihydroprogesterone (5alphap) ...
23402769 - Nutrient transporters: the achilles' heel of anabolism.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-01
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  9     ISSN:  1538-8514     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3322-9     Citation Subset:  IM    
Copyright Information:
©2010 AACR.
Affiliation:
Centre for Experimental Cancer Medicine, Institute of Cancer, John Vane Science Centre, Barts and the London School of Medicine, Queen Mary College, Charterhouse Square, London EC1M 6BQ, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Next Document:  Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vi...